These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37442083)

  • 1. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
    Huang S; Xiong C; Tan K
    Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
    Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
    Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
    J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
    Chen S; Yang Y; Wang R; Fang J
    Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
    Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
    Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.
    Clarke E; Eriksen JG; Barrett S
    Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
    Vathiotis IA; Johnson JM; Luginbuhl A; Cognetti D; Curry J; Argiris A
    Cancer Treat Rev; 2022 Sep; 109():102437. PubMed ID: 35868194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
    Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
    Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.
    Ran X; Yang K
    Drug Des Devel Ther; 2017; 11():2007-2014. PubMed ID: 28721019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.